Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Amotiv Limited

KHTRF
Current price
3.70 USD 0 USD (0.00%)
Last closed 5.29 CAD
ISIN CA4990531069
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange TO
Capitalization 579 254 624 CAD
Yield for 12 month -7.18 %
1Y
3Y
5Y
10Y
15Y
KHTRF
21.11.2021 - 28.11.2021

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada. Address: 3400 de Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.32 CAD

P/E ratio

Dividend Yield

Current Year

+329 578 859 CAD

Last Year

+294 797 238 CAD

Current Quarter

+86 968 112 CAD

Last Quarter

+74 508 949 CAD

Current Year

+153 293 800 CAD

Last Year

+138 641 454 CAD

Current Quarter

+41 874 317 CAD

Last Quarter

+34 358 851 CAD

Key Figures KHTRF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 49 994 312 CAD
Operating Margin TTM 3.07 %
PE Ratio
Return On Assets TTM 0.21 %
PEG Ratio 2 856.67
Return On Equity TTM -2.21 %
Wall Street Target Price 10.32 CAD
Revenue TTM 333 602 721 CAD
Book Value 7.56 CAD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 4.90 %
Dividend Yield
Gross Profit TTM 138 641 455 CAD
Earnings per share -0.16 CAD
Diluted Eps TTM -0.16 CAD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY 800.00 %
Profit Margin -5.25 %

Dividend Analytics KHTRF

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History KHTRF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation KHTRF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 263.16
Enterprise Value Revenue 1.45
Price Sales TTM 1.76
Enterprise Value EBITDA 11.63
Price Book MRQ 0.77

Financials KHTRF

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators KHTRF

For 52 weeks

5.11 CAD 6.26 CAD
50 Day MA 5.83 CAD
Shares Short Prior Month 3 138 062
200 Day MA 5.39 CAD
Short Ratio 49.42
Shares Short 3 123 744
Short Percent 2.52 %